Brief: Alphamab Oncology Says Jiangsu Alphamab Engages With Suzhou Alphamab For Tech Development
08/08/2025 16:14
Aug 8 (Reuters) - Alphamab Oncology 9966.HK: JIANGSU ALPHAMAB ENGAGES WITH SUZHOU ALPHAMAB FOR TECH DEVELOPMENT UNDER DEAL, SUZHOU ALPHAMAB TO DEVELOP PRODUCTION FOR UNIT'S BISPECIFIC ANTIBODY-DRUG CONJUGATE Further company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)